## REMARKS

Applicants are in receipt of a Notice of Allowance issued in the above-referenced application on January 25, 2006. Applicants submit herewith a request pursuant to 37 C.F.R. §1.312 for admission of five additional claims without withdrawing the case from issue. The proposed new claims are dependent claims which are directed to specific embodiments encompassed by the allowed claims and which are specifically disclosed in the original specification as filed. No new matter is added by these claims and no further search is required, as the new claims incorporate all the allowable features of allowed independent Claim 28. Entry and inclusion of new dependent Claims 40-44 in the patent issuing from this application are respectfully requested.

New Claim 40, dependent from Claim 28, is directed to specific modes of administration of the antigenic vaccine peptide defined in Claim 28. Support for new Claim 40 may be found in the specification on page 25, lines 20-28.

New Claim 41, dependent from Claim 40, is directed to a specific administration protocol for the antigenic vaccine peptide, comprising a primary administration of the peptide followed by one or more "booster" administrations. Support for new Claim 41 may be found in the specification on page 26, lines 11-18.

New Claim 42, dependent from Claim 41, is directed to a pharmaceutical formulation comprising the antigenic vaccine peptide formulated with an adjuvant. Support for new Claim 42 may be found in the specification on page 22, line 4, to page 23, line 2.

New Claim 43, dependent from Claim 42, is directed to a preferred adjuvant, i.e., alum. Support for new Claim 43 may be found in the specification on page 22, line 4.

New Claim 44, dependent from Claim 28, is directed to an embodiment of the antigenic vaccine peptide that includes an N-terminal or C-terminal cysteine residue. Support for new Claim 44 may be found throughout the specification, for example, at page 17, lines 1-2; page 20, line 5; and page 21, lines 17-21.

Entry of the foregoing amendments without withdrawing this case from issue is respectfully requested. This request is being filed concurrently with payment of the issue fee and publication fee.

Appln. Ser. No. 09/943,334 Atty. Docket No.: TCS-411.1P US-1

Respectfully submitted,

Leon R. Yankwich, Reg. No. 30,237 David G. O'Brien, Reg. No. 46,125

Attorneys for Applicants

YANKWICH & ASSOCIATES, P.C.

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700 telefax: (617) 374-0055

## CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Mail Stop: ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Nasim G. Memon